Mounjaro and Bone Density: Does Weight Loss on Tirzepatide Affect Your Bones?

Mounjaro (tirzepatide) is one of the most effective weight-loss treatments available today, but rapid weight loss from any cause can affect bone mineral density. For patients already at risk of osteoporosis, particularly postmenopausal women, understanding how tirzepatide interacts with bone health is essential before starting treatment. In this guide, we explain what the clinical evidence shows, who needs monitoring, and how to protect your bones while losing weight on Mounjaro.

Current evidence suggests that bone mineral density (BMD) reductions seen during tirzepatide treatment are largely proportional to the amount of weight lost, rather than a direct drug effect. A 2026 study published in The Journal of Clinical Endocrinology and Metabolism found that patients using GLP-1 receptor agonists experienced similar BMD declines at the hip and femoral neck as a control group who lost comparable weight through other means. However, the SURMOUNT-1 DXA substudy showed that approximately 25 per cent of total weight lost on tirzepatide was lean mass, and lean mass loss can indirectly accelerate bone turnover. For anyone with existing osteoporosis risk factors, a baseline DEXA scan before starting Mounjaro is strongly recommended.

Bone is a living tissue that constantly remodels itself. It responds to mechanical loading: the heavier you are, the more force your skeleton bears with every step, and the denser your bones tend to be. When you lose a significant amount of weight, that mechanical stimulus decreases, and bone density can fall as a consequence.

Furthermore, caloric restriction itself can reduce the availability of calcium, vitamin D, and protein needed for bone maintenance. Rapid weight loss compounds this effect because the skeleton has less time to adapt to the reduced loading. This is true whether weight is lost through diet, bariatric surgery, or medication such as tirzepatide.

According to NICE guideline CG146, adults over 50 with clinical risk factors for fragility fracture should be assessed using validated tools such as FRAX or QFracture. Starting a treatment that produces substantial weight loss is, in our view, a sensible trigger for that assessment.

The SURMOUNT and SURPASS clinical trial programmes did not identify osteoporosis or clinically significant bone density loss as an adverse event associated with tirzepatide. The MHRA summary of product characteristics for Mounjaro does not list fracture or osteoporosis among its known risks.

However, more focused research tells a nuanced story. A study published in The Journal of Clinical Endocrinology and Metabolism in 2026 followed 255 patients using semaglutide or tirzepatide (92 per cent female, mean age 64) over a median of 17 months. Both the GLP-1 receptor agonist group and the control group experienced significant BMD declines at the total hip and femoral neck, with similar magnitude between groups. In other words, the bone loss tracked with the weight loss, not with the drug itself.

Similarly, a retrospective cohort analysis presented at ENDO 2025 found that, after an average follow-up of 34 months, patients on GLP-1 receptor agonists had BMD declines of 1.6 per cent at the lumbar spine, 1.8 per cent at the femoral neck, and 2.8 per cent at the total hip. The total hip decline was significantly associated with the amount of weight lost.

Additionally, the SURMOUNT-1 DXA substudy revealed that about 25 per cent of total weight lost on tirzepatide was lean body mass, with lean mass declining by 10.9 per cent over 72 weeks compared with 2.6 per cent in the placebo group. Lean mass loss is relevant to bone health because muscle and bone are mechanically coupled: weaker muscles exert less force on bone, which can accelerate resorption. If you are concerned about preserving lean mass on Mounjaro, resistance training and adequate protein intake are essential protective strategies.

One reason tirzepatide is of particular scientific interest is its dual mechanism: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. Preclinical research published in the Journal of Endocrinology in 2025 showed that GIP receptor activation promotes osteoblast survival and inhibits osteoclast activity, meaning it could theoretically support bone formation.

In practice, however, this theoretical advantage has not yet been confirmed in large human trials. A 2025 mouse model study found that tirzepatide promoted bone loss through changes in gut microbial metabolites, adding further complexity. A retrospective cohort study using the TriNetX database compared tirzepatide users with users of other GLP-1 receptor agonists and did not find a significant difference in osteoporosis risk between the groups.

The honest clinical position is that tirzepatide’s GIP component may offer some bone protection relative to selective GLP-1 receptor agonists, but the weight-loss-driven bone loss likely outweighs any protective effect. More long-term data are needed, and the SURMOUNT-MMO trial will provide further clarity in the years ahead.

Not every patient taking Mounjaro faces the same level of bone risk. The following groups warrant closer monitoring:

• Postmenopausal women, especially those not on hormone replacement therapy
• Adults over 65, regardless of sex
• Anyone with a prior fragility fracture
• Patients with a family history of hip fracture
• Those taking long-term corticosteroids or other bone-depleting medications
• Patients with coeliac disease, inflammatory bowel disease, or other malabsorption conditions
• Smokers and heavy alcohol consumers
• Anyone with a low body mass index at baseline (BMI under 30) who is losing weight rapidly

If you fall into one or more of these categories, a proactive approach to bone monitoring is essential. At CutKilo, we discuss bone health during initial consultations for patients with identifiable risk factors.

The gold standard for measuring bone mineral density is a DEXA (dual-energy X-ray absorptiometry) scan. This painless, low-radiation test takes roughly 10 minutes and provides precise measurements at the hip and lumbar spine. DEXA London, CutKilo’s sister service at the same 86 Harley Street clinic, offers bone density scanning alongside body composition assessments for patients on GLP-1 therapy.

For patients with risk factors, we recommend a baseline DEXA scan before or shortly after starting Mounjaro, followed by a repeat scan at 12 to 24 months to track any changes. Your doctor should also consider a FRAX assessment to estimate your 10-year fracture probability, as recommended by NICE guideline CG146.

Blood tests for vitamin D (25-hydroxyvitamin D), calcium, and bone turnover markers (such as CTX and P1NP) can provide additional information about bone metabolism during treatment.

Fortunately, there is plenty you can do to support bone health while benefiting from tirzepatide therapy:

Resistance training: Weight-bearing and resistance exercise is the single most effective non-pharmacological intervention for bone density. Aim for at least two sessions per week that include exercises such as squats, lunges, deadlifts, and overhead presses. Impact activities like brisk walking, jogging, or stair climbing also stimulate bone remodelling.

Adequate protein: Protein is a structural component of bone. Aim for 1.2 to 1.6 grams per kilogram of body weight daily, prioritising leucine-rich sources such as eggs, dairy, poultry, and fish. This also helps preserve the lean mass that supports skeletal loading.

Calcium and vitamin D: Adults should aim for 700 mg of calcium daily (the UK recommended nutrient intake) from dietary sources such as dairy, fortified plant milks, tinned sardines, and dark leafy greens. Vitamin D supplementation of 10 micrograms (400 IU) daily is recommended by Public Health England for all UK adults during autumn and winter, and year-round for those with limited sun exposure.

Avoid excessive caloric restriction: While Mounjaro naturally reduces appetite, deliberately restricting calories below 1,200 per day increases the risk of nutrient deficiencies that harm bone. Work with your clinical team to ensure your dietary intake supports both weight loss and skeletal health.

Discuss bisphosphonates if indicated: For patients diagnosed with osteoporosis or at high fracture risk, bone-protective medications such as alendronate or risedronate may be appropriate alongside tirzepatide therapy. Your GP or endocrinologist can advise on this.

Mounjaro does not appear to cause bone loss beyond what would be expected from the degree of weight loss achieved. The bone density changes seen in clinical studies are driven primarily by reduced mechanical loading and lean mass loss, not by a direct pharmacological effect of tirzepatide on bone. For most patients, the metabolic benefits of treating obesity far outweigh the skeletal risks. Nevertheless, patients with existing osteoporosis risk factors should have a baseline DEXA scan, maintain adequate protein, calcium, and vitamin D intake, engage in regular resistance and weight-bearing exercise, and discuss repeat bone density monitoring with their doctor at 12 to 24 months.

Does Mounjaro directly cause osteoporosis? No. The MHRA summary of product characteristics does not list osteoporosis as a known adverse effect. Bone density reductions observed in studies appear proportional to weight loss rather than a direct drug effect. However, rapid weight loss from any cause can reduce BMD, so monitoring is important for at-risk patients.

Should I get a bone density scan before starting Mounjaro? If you are a postmenopausal woman, over 65, have a history of fracture, or have other risk factors for osteoporosis, a baseline DEXA scan is strongly recommended. For younger patients without risk factors, routine screening is not usually necessary but can be discussed with your doctor.

Can exercise prevent bone loss while on Mounjaro? Yes. Resistance training and weight-bearing exercise are the most effective ways to maintain bone density during weight loss. Aim for at least two resistance sessions and 150 minutes of moderate activity per week.

Is tirzepatide better for bones than semaglutide because of the GIP component? Preclinical research suggests GIP receptor activation may support bone formation, but this has not been confirmed in human trials. Retrospective data have not shown a significant difference in osteoporosis risk between tirzepatide and other GLP-1 receptor agonists. More research is needed.

How much bone density loss is normal during weight loss? Studies suggest BMD declines of 1 to 3 per cent at the hip and lumbar spine over 12 to 34 months of GLP-1 receptor agonist therapy. This is consistent with what is seen after bariatric surgery or significant dietary weight loss. Whether this translates into increased fracture risk depends on your baseline bone density and other risk factors.